share_log

Arcutis Biotherapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Watanabe Todd Franklin

Arcutis Biotherapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Watanabe Todd Franklin

Arcutis Biotherapeutics | 4：持股变动声明-高管 Watanabe Todd Franklin
美股sec公告 ·  05/03 16:29
Moomoo AI 已提取核心信息
Todd Franklin Watanabe, associated with Arcutis Biotherapeutics, completed a sale of 13,783 shares of common stock on May 2, 2024. The transaction was executed at a price of $8.7378 per share, resulting in a total sale value of approximately $120,433. Following the sale, Watanabe directly holds 860,750 shares of the company. The sale took place in the open market and was part of a planned disposition of shares. Additionally, Watanabe has indirect beneficial ownership of 231,140 shares through trusts and an LLC.
Todd Franklin Watanabe, associated with Arcutis Biotherapeutics, completed a sale of 13,783 shares of common stock on May 2, 2024. The transaction was executed at a price of $8.7378 per share, resulting in a total sale value of approximately $120,433. Following the sale, Watanabe directly holds 860,750 shares of the company. The sale took place in the open market and was part of a planned disposition of shares. Additionally, Watanabe has indirect beneficial ownership of 231,140 shares through trusts and an LLC.
与Arcutis Biotherapeutics相关的渡边托德·富兰克林于2024年5月2日完成了13,783股普通股的出售。该交易以每股8.7378美元的价格执行，总销售价值约为120,433美元。出售后，渡边直接持有该公司860,750股股份。此次出售是在公开市场上进行的，是计划处置股票的一部分。此外，渡边通过信托和有限责任公司间接拥有231,140股股票的受益所有权。
与Arcutis Biotherapeutics相关的渡边托德·富兰克林于2024年5月2日完成了13,783股普通股的出售。该交易以每股8.7378美元的价格执行，总销售价值约为120,433美元。出售后，渡边直接持有该公司860,750股股份。此次出售是在公开市场上进行的，是计划处置股票的一部分。此外，渡边通过信托和有限责任公司间接拥有231,140股股票的受益所有权。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息